EA030850B1 - Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций - Google Patents

Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций Download PDF

Info

Publication number
EA030850B1
EA030850B1 EA201691766A EA201691766A EA030850B1 EA 030850 B1 EA030850 B1 EA 030850B1 EA 201691766 A EA201691766 A EA 201691766A EA 201691766 A EA201691766 A EA 201691766A EA 030850 B1 EA030850 B1 EA 030850B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino
mmol
methyl
tert
alkyl
Prior art date
Application number
EA201691766A
Other languages
English (en)
Russian (ru)
Other versions
EA201691766A1 (ru
Inventor
Вирендер Сингх Аулакх
Энтони Казаре
Сяодун Лин
Мика Линдвалль
Глен Макинрой
Хейнц Эрнст Моузер
Фолькерт Рек
Меилиана Тжандра
Роберт Лоуэлл Симмонс
Арегахегн Йифру
Цинмин Чжу
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201691766A1 publication Critical patent/EA201691766A1/ru
Publication of EA030850B1 publication Critical patent/EA030850B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201691766A 2014-03-24 2015-03-23 Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций EA030850B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969735P 2014-03-24 2014-03-24
US201462088304P 2014-12-05 2014-12-05
PCT/US2015/022011 WO2015148379A1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
EA201691766A1 EA201691766A1 (ru) 2016-12-30
EA030850B1 true EA030850B1 (ru) 2018-10-31

Family

ID=52808201

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691766A EA030850B1 (ru) 2014-03-24 2015-03-23 Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций

Country Status (37)

Country Link
US (4) US9174978B2 (cg-RX-API-DMAC7.html)
EP (2) EP3511328B1 (cg-RX-API-DMAC7.html)
JP (1) JP6153674B2 (cg-RX-API-DMAC7.html)
KR (1) KR101733441B1 (cg-RX-API-DMAC7.html)
CN (1) CN106164072B (cg-RX-API-DMAC7.html)
AP (1) AP2016009374A0 (cg-RX-API-DMAC7.html)
AU (1) AU2015236369B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016020333B1 (cg-RX-API-DMAC7.html)
CA (1) CA2939254C (cg-RX-API-DMAC7.html)
CL (1) CL2016002285A1 (cg-RX-API-DMAC7.html)
CU (1) CU24441B1 (cg-RX-API-DMAC7.html)
CY (1) CY1121701T1 (cg-RX-API-DMAC7.html)
DK (2) DK3511328T3 (cg-RX-API-DMAC7.html)
EA (1) EA030850B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16073620A (cg-RX-API-DMAC7.html)
ES (2) ES2862203T3 (cg-RX-API-DMAC7.html)
GT (1) GT201600183A (cg-RX-API-DMAC7.html)
HR (1) HRP20190501T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042134T2 (cg-RX-API-DMAC7.html)
IL (1) IL247259B (cg-RX-API-DMAC7.html)
LT (1) LT3122745T (cg-RX-API-DMAC7.html)
MA (1) MA39777B1 (cg-RX-API-DMAC7.html)
MX (1) MX373444B (cg-RX-API-DMAC7.html)
MY (1) MY179292A (cg-RX-API-DMAC7.html)
PE (1) PE20161371A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501577B1 (cg-RX-API-DMAC7.html)
PL (1) PL3122745T3 (cg-RX-API-DMAC7.html)
PT (1) PT3122745T (cg-RX-API-DMAC7.html)
RS (1) RS58509B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606711UA (cg-RX-API-DMAC7.html)
SI (1) SI3122745T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900218T1 (cg-RX-API-DMAC7.html)
SV (1) SV2016005274A (cg-RX-API-DMAC7.html)
TW (1) TWI714525B (cg-RX-API-DMAC7.html)
UA (1) UA121383C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015148379A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605565B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10919887B2 (en) 2015-09-23 2021-02-16 Novartis Ag Salts and solid forms of a monobactam antibiotic
US11414411B2 (en) 2017-08-02 2022-08-16 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180282331A1 (en) 2015-11-09 2018-10-04 Wockhardt Limited 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS
JP7184646B2 (ja) * 2015-12-15 2022-12-06 メルク・シャープ・アンド・ドーム・エルエルシー ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法
MX2018010878A (es) 2016-03-07 2018-11-09 Merck Sharp & Dohme Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
IL269390B (en) 2017-03-20 2022-08-01 Broad Inst Inc Compounds and methods for the treatment of parasitic diseases
WO2019058346A1 (en) * 2017-09-22 2019-03-28 Novartis Ag MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
KR102455390B1 (ko) * 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
MX2020003581A (es) 2017-10-02 2020-07-22 Merck Sharp & Dohme Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
JP7280273B2 (ja) 2018-01-29 2023-05-23 メッドシャイン ディスカバリー インコーポレイテッド 細菌感染を治療するための単環β－ラクタム化合物
KR102017784B1 (ko) * 2018-04-11 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
KR102017785B1 (ko) * 2018-05-17 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
US20220002288A1 (en) 2018-11-13 2022-01-06 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
US12310948B2 (en) 2018-12-18 2025-05-27 Shenzhen Optimum Biological Technology Co., Ltd Application of monocyclic β-lactam compound in pharmacy
CN114787158B (zh) * 2019-11-22 2023-10-24 苏州二叶制药有限公司 磺酰脲环取代的单环β-内酰胺类抗生素
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
WO2021121387A1 (zh) 2019-12-19 2021-06-24 南京明德新药研发有限公司 化合物在制药中的应用
EP3838266A1 (en) 2019-12-20 2021-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN115210231B (zh) * 2020-07-16 2024-10-08 宁夏农林科学院 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
KR20240105442A (ko) * 2021-11-18 2024-07-05 머크 샤프 앤드 돔 엘엘씨 크로만 아미딘 모노박탐 항생제
CN115304594B (zh) 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093376A2 (en) * 1982-04-30 1983-11-09 Takeda Chemical Industries, Ltd. 1-Sulfo-2-azetidinone derivatives, their production and use
WO2012073138A1 (en) * 2010-11-29 2012-06-07 Pfizer Inc. Monobactams
WO2013110643A1 (en) * 2012-01-24 2013-08-01 Aicuris Gmbh & Co. Kg Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
JPS58189176A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd １−スルホ−２−アゼチジノン誘導体およびその製造法
US4782147A (en) * 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
EP0090505B1 (en) 1982-03-03 1990-08-08 Genentech, Inc. Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it
KR900005112B1 (ko) 1982-05-31 1990-07-19 반유세이야꾸 가부시끼가이샤 2-옥소-1-아제티딘술폰산 유도체의 제조방법
EP0096297B1 (de) 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd ２−オキソ−１−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
AU1102399A (en) 1997-10-21 1999-05-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
EP1053321A1 (en) 1998-02-09 2000-11-22 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
US20100009957A1 (en) 2006-09-27 2010-01-14 Blizzard Timothy A Novel inhibitors of beta-lactamase
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
ME02666B (me) 2008-10-31 2017-06-20 Shionogi & Co Cefalosporin sa kateholskom grupom
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
IN2012DN01920A (cg-RX-API-DMAC7.html) 2009-09-03 2015-07-24 Schering Corp
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011061760A1 (en) 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
JP2012027846A (ja) 2010-07-27 2012-02-09 Sony Corp 情報処理装置、情報表示方法及びコンピュータプログラム
ES2572527T3 (es) 2011-08-25 2016-06-01 Merck Sharp & Dohme Corp. Inhibidores de PDE10 de pirimidina
US8754102B2 (en) 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2881169C (en) 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
WO2015103583A1 (en) 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093376A2 (en) * 1982-04-30 1983-11-09 Takeda Chemical Industries, Ltd. 1-Sulfo-2-azetidinone derivatives, their production and use
WO2012073138A1 (en) * 2010-11-29 2012-06-07 Pfizer Inc. Monobactams
WO2013110643A1 (en) * 2012-01-24 2013-08-01 Aicuris Gmbh & Co. Kg Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10919887B2 (en) 2015-09-23 2021-02-16 Novartis Ag Salts and solid forms of a monobactam antibiotic
US11414411B2 (en) 2017-08-02 2022-08-16 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof

Also Published As

Publication number Publication date
JP6153674B2 (ja) 2017-06-28
SG11201606711UA (en) 2016-10-28
CU24441B1 (es) 2019-09-04
HUE042134T2 (hu) 2019-06-28
MY179292A (en) 2020-11-03
IL247259A0 (en) 2016-09-29
ZA201605565B (en) 2017-09-27
AU2015236369A1 (en) 2016-09-01
CA2939254C (en) 2023-02-14
CY1121701T1 (el) 2020-07-31
EP3122745B1 (en) 2019-02-27
RS58509B1 (sr) 2019-04-30
SI3122745T1 (sl) 2019-05-31
ECSP16073620A (es) 2018-12-31
NZ723114A (en) 2020-12-18
HRP20190501T1 (hr) 2019-05-03
EP3511328B1 (en) 2021-03-03
AP2016009374A0 (en) 2016-08-31
US10369138B2 (en) 2019-08-06
KR101733441B1 (ko) 2017-05-10
CL2016002285A1 (es) 2016-12-30
WO2015148379A1 (en) 2015-10-01
TWI714525B (zh) 2021-01-01
CA2939254A1 (en) 2015-10-01
LT3122745T (lt) 2019-04-10
UA121383C2 (uk) 2020-05-25
EA201691766A1 (ru) 2016-12-30
IL247259B (en) 2020-02-27
US20150266867A1 (en) 2015-09-24
US9174978B2 (en) 2015-11-03
GT201600183A (es) 2018-12-18
KR20160110541A (ko) 2016-09-21
BR112016020333B1 (pt) 2022-08-09
PE20161371A1 (es) 2016-12-21
SV2016005274A (es) 2018-06-12
AU2015236369B2 (en) 2017-02-16
SMT201900218T1 (it) 2019-05-10
MA39777B1 (fr) 2019-03-29
MA39777A (fr) 2017-02-01
EP3511328A1 (en) 2019-07-17
PH12016501577B1 (en) 2022-04-29
PT3122745T (pt) 2019-04-30
CN106164072A (zh) 2016-11-23
EP3122745A1 (en) 2017-02-01
DK3122745T3 (en) 2019-04-08
ES2719136T3 (es) 2019-07-08
US20160051523A1 (en) 2016-02-25
DK3511328T3 (da) 2021-03-22
US20190231752A1 (en) 2019-08-01
CN106164072B (zh) 2019-10-01
JP2017510580A (ja) 2017-04-13
BR112016020333A2 (pt) 2017-10-24
TW201540712A (zh) 2015-11-01
CU20160131A7 (es) 2017-02-02
MX373444B (es) 2020-04-30
PL3122745T3 (pl) 2019-08-30
US20200276169A1 (en) 2020-09-03
MX2016011822A (es) 2016-12-02
PH12016501577A1 (en) 2016-10-03
ES2862203T3 (es) 2021-10-07

Similar Documents

Publication Publication Date Title
AU2015236369B2 (en) Monobactam organic compounds for the treatment of bacterial infections
CA2715839C (en) Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
TWI432426B (zh) Ｃ型肝炎病毒抑制劑
JP6670333B2 (ja) メタロ−β−ラクタマーゼ阻害剤としての３−テトラゾリル−ベンゼン−１，２−ジスルホンアミド誘導体
TWI400072B (zh) Ｃ型肝炎病毒抑制劑
US11332459B2 (en) Benzimidazole derivatives and their uses
KR20200115550A (ko) 키나제 억제제로서의 아미노피롤로트리아진
MX2011010478A (es) Inhibidores del virus de la hepatitis c.
TW202140499A (zh) 巨環ｒｉｐ２－激酶抑制劑
HK1230592A1 (en) Monobactam organic compounds for the treatment of bacterial infections
HK1230592B (en) Monobactam organic compounds for the treatment of bacterial infections
NZ723114B2 (en) Monobactam organic compounds for the treatment of bacterial infections

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ TM